Understanding Biomarkers in Neuroblastoma: Signposts on the Road to Recovery

Introduction

Biomarkers are specific molecules that indicate the presence of a disease or the effects of treatment on the body. In the context of neuroblastoma, a pediatric cancer originating from neural crest cells, biomarkers play a crucial role in diagnosis, prognosis, and treatment decisions[1][2]. The importance of biomarkers in modern oncology cannot be overstated, as they are integral to the development of personalized medicine and targeted therapies[1].

What Are Neuroblastoma-Related Biomarkers?

Neuroblastoma is a heterogeneous solid tumor that accounts for approximately 10% of all childhood cancers[1]. It exhibits a range of biological characteristics, including spontaneous regression in low-risk groups to metastasis and death in high-risk cases[1]. Common biomarkers in neuroblastoma include MYCN amplification, ALK mutations, and GD2 expression, which are used for classification, prognosis, and as therapeutic targets[1][2][3][4].

Key Biomarkers in Neuroblastoma and Their Significance

MYCN Amplification

MYCN is a member of the MYC family of oncogenes, and its amplification is found in about 25% of neuroblastoma cases, correlating with high-risk disease and poor prognosis[2]. MYCN amplification is a well-established genetic marker of risk in neuroblastoma, and targeting MYCN-amplified neuroblastoma is a potential therapeutic option[2][6].

ALK Mutations

The ALK gene plays a role in neuroblastoma, with activating missense single nucleotide variants leading to increased kinase activity[3]. ALK mutations are present across all stages and risk groups of neuroblastoma and are significant as they can be targeted by specific therapies[3][7].

GD2 Expression

GD2 is a disialoganglioside highly expressed by almost all neuroblastomas and serves as a target for immunotherapy[4]. Anti-GD2 monoclonal antibodies have transformed the management of neuroblastoma, with their use leading to improved outcomes[4].

Other Important Biomarkers

Chromosomal abnormalities, ploidy status, and gene expression profiles are additional biomarkers that contribute to the understanding and treatment of neuroblastoma[1][8].

The Role of Biomarkers in Treatment Decisions

Biomarkers are essential in the era of personalized medicine, guiding treatment selection and monitoring response to therapy in neuroblastoma patients[1]. They help in stratifying patients into different risk groups, which is crucial for determining the intensity of treatment required[8].

Future of Biomarkers in Neuroblastoma Research

Emerging biomarkers hold the potential to further refine treatment options and improve outcomes for neuroblastoma patients[1]. The continuous discovery of novel biomarkers is vital for early detection, predicting disease course, and developing new targeted therapies[1][5].

Conclusion

The growing importance of biomarkers in managing neuroblastoma underscores the need for ongoing research. This research not only advances our understanding of the disease but also provides hope and support for families affected by neuroblastoma[1].

Citations:
[1] https://pubmed.ncbi.nlm.nih.gov/34580780/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784814/
[3] https://www.nature.com/articles/s41416-023-02208-y
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358363/
[5] https://link.springer.com/article/10.1007/s11864-021-00898-1
[6] https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.624079/full
[7] https://ascopubs.org/doi/full/10.1200/PO.20.00181
[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699935/
[9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377415/
[10] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584162/
[11] https://www.nature.com/articles/s41598-021-83619-w
[12] https://www.pnas.org/doi/10.1073/pnas.1710901115
[13] https://www.chop.edu/cccr/area-of-study/alk-inhibition-treatment-alk-driven-neuroblastoma
[14] https://royalsocietypublishing.org/doi/10.1098/rsob.190056
[15] https://aacrjournals.org/cancerdiscovery/article/8/3/320/6193/MYC-Drives-a-Subset-of-High-Risk-Pediatric
[16] https://pubmed.ncbi.nlm.nih.gov/34250410/
[17] https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-022-00368-2
[18] https://www.pnas.org/doi/full/10.1073/pnas.1208215109
[19] https://www.nature.com/articles/s41598-018-37240-z
[20] https://www.cancer.org/cancer/types/neuroblastoma/detection-diagnosis-staging/staging.html
[21] https://www.science.org/doi/10.1126/sciadv.adg6693
[22] https://www.esmo.org/oncology-news/alk-mutations-and-amplifications-are-independent-predictors-of-poorer-survival-in-high-risk-neuroblastoma
[23] https://journals.sagepub.com/doi/10.1177/1176935119832910
[24] https://www.nature.com/articles/s41467-020-14682-6
[25] https://ascopubs.org/doi/10.1200/JCO.21.00086